Background and Aims: Several studies have suggested significant associations between environmental factors and the risk of developing inflammatory bowel disease [IBD]. However, data supporting the role of antibiotics are conflicting. The aim of this study was to evaluate the association between antibiotic use and new-onset IBD.
Introduction
Inflammatory bowel diseases [IBD] , consisting of Crohn's disease [CD] and ulcerative colitis [UC] , are chronic idiopathic inflammatory conditions. Despite advances in the management of IBD, the pathogenesis of IBD is incompletely understood. The key contributors to the pathogenesis of IBD are thought to be genetics, host immune response and environmental factors. 1 The low concordance rate of IBD [approximately 35-50% for CD and 15% for UC] in identical twins suggests that genetic factors do not completely explain the disease aetiology. [2] [3] [4] Likewise, the increasing incidence of IBD worldwide including North America, Europe, Australia and Asia over the past 50 years suggests the important role of host immune response and environmental factors. [5] [6] [7] Emerging evidence suggests that disturbances in the gut microbiota and their interaction with the host immune system in a genetically susceptible individual may be the fundamental development of IBD. 1, 8 Changes in microbial diversity and loss of protective microbial species have been demonstrated in patients with IBD. 1 In particular, some dietary changes and antibiotic exposure have been shown to alter gut microbiota. 9 Several studies have suggested significant associations between environmental factors, including cigarette smoking 10, 11 and westernized diet, 12, 13 and the risk of developing IBD. However, data for antibiotics are conflicting. [14] [15] [16] [17] [18] [19] [20] A previous metaanalysis has shown a modest association between antibiotic use and IBD development (pooled odds ratio [OR], 1.57; 95% confidence interval [CI], 1.27-1.94). 15 Antibiotic use increased the odds of CD development [OR, 1.74; 95% CI, 1.35-2.23] but not UC [OR, 1.08; 95% CI, 0.91-1.27]. The authors noted a great deal of heterogeneity across the studies. For example, a study from the UK using the General Practice Research Database 20 and a study from Canada using the University of Manitoba IBD Database 16 relied upon diagnostic and prescription codes to identify cases and exposures. As a result, misclassification bias may have occurred. Furthermore, some important predisposing factors to development of IBD, including cigarette smoking status and family history of IBD, could not be identified by administrative data. On the other hand, previous studies using a selfadministered questionnaire 14, [17] [18] [19] to assess antibiotic exposure were limited due to recall bias. Moreover, using prevalent patients may overrepresent those who regularly follow up, and may not include patients who migrated, lived in rural regions or those with indolent disease who were followed by their primary physician. 19 Hence, the implications of antibiotic use as a predisposing factor in IBD aetiology remain unresolved, hindering our understanding of the pathogenesis of IBD. Therefore, to address this gap in knowledge, the present study sought to evaluate the association between the antibiotic use and new-onset IBD [both CD and UC] in a population-based cohort from Olmsted County, Minnesota.
Material and Methods

Rochester Epidemiology Project
The resources of the Rochester Epidemiology Project were used to identify permanent residents of Olmsted County, Minnesota, who were diagnosed with IBD and non-IBD between 1980 and 2010. The Rochester Epidemiology Project is a unique medical records linkage system developed in the 1950s and supported by the National Institutes of Health. 21 It exploits the fact that virtually all the health care for residents of Olmsted County is provided by two organizations: the Mayo Medical Center, consisting of the Mayo Clinic and its two affiliated hospitals [Rochester Methodist and St. Mary's], and Olmsted Medical Center, consisting of a smaller multispecialty clinic and its affiliated hospital [Olmsted Community Hospital]. In any 4-year period, over 95% of county residents are examined at either one of the two healthcare systems. 22 Diagnoses generated from all outpatients visits, emergency room visits, hospitalizations, nursing home visits, laboratory, surgical procedures, medical treatment, autopsy examination and death certification are contained in a single comprehensive medical records linkage system. Thus, this population-based data resource ensures virtually complete case ascertainment and follow-up in a well-defined geographical region. 23 
Study population
This population-based case-control study comprised 736 Olmsted County residents first diagnosed with IBD [339 CD and 397 UC] between 1980 and 2010 according to well-defined criteria as previously described. 5, [24] [25] [26] The index date was based on the first IBD diagnosis. For each case with IBD diagnosis, two controls were randomly selected from Olmsted County residents without an IBD diagnosis after matching for age, sex and index date of IBD diagnosis, which assigned the index date corresponding to the index date of IBD diagnosis. To determine whether IBD developed or not, individuals in the control cohort were followed through their medical history from the index date until death, emigration or the end of the study [June 30, 2016] , whichever came first. We investigated the impact of age on the association between antibiotic use and IBD development. Age groups at index date were stratified as <18 years, 18-60 years and > 60 years.
Antibiotic use
Data on the use of antibiotics with regard to class of antibiotic, indication, duration and number of antibiotic courses were collected for 5 years before the index date. Because antibiotics are commonly prescribed for symptoms of IBD prior to diagnosis, antibiotic use within 3 months prior to the index date was excluded. 
Statistical analysis
Assuming the prevalence of antibiotic use in the control group ranged from 25 to 50%, a sample size of at least 330 cases and 660 controls in each CD and UC cohort was required to detect an OR of at least 2 with a power of 80% at a two-sided significance level of 0.05. Descriptive statistical analysis was used to determine baseline characteristics of IBD cases and controls. To compare categorical variables, a chi-square test or Fisher exact test was used. To compare continuous variables, Student's t-test or Mann-Whitney U-test was used. Antibiotic use and potential confounding factors (i.e. first degree family history of IBD, current cigarette smoking, former cigarette smoking, obesity [body mass index ≥ 30 kg/m 2 ], daily aspirin use and statins use) were tested by univariate analysis. Daily aspirin use was defined as taking aspirin at least once a day for at least 3 months before the index date. Statin use was defined as taking a statin [pravastatin, atorvastatin, simvastatin, rosuvastatin, fluvastatin, lovastatin] for at least 3 months before the index date. A multivariate analysis model was then analysed using unconditional logistic regression models to estimate the adjusted OR [AOR] and 95% CI. Age, sex and any variables with a p < 0.1 in the univariate analysis were included in the multivariate analysis. Separate analyses for IBD subtypes [CD and UC] and age groups at the index date were performed. To evaluate whether there was a dose-dependent relationship between antibiotic use and the risk of IBD development, the analysis was also stratified by the cumulative duration of antibiotic use and by the number of antibiotic courses. An alpha-level of 0.05 was considered as statistically significant. Statistical analyses were performed by using the JMP 10 statistical software package [SAS Institute Inc., Cary, NC, USA].
Results
A total of 736 incident IBD cases and 1472 controls were included in this study. This sample size was sufficient to achieve the a priori statistical power assumptions for the study. Table 1 shows the demographic characteristics of the IBD cases and controls. By study design, there were no differences in the age and sex distribution between IBD cases and controls. In both IBD cases and controls, the median age at the index date was 34 years [range, 1. Table 5 . The significant association between antibiotic use and the risk of IBD remained regardless of year of antibiotic use before IBD 
Discussion
The results of this population-based case-control study demonstrate a strong association between antibiotic use and the risk of either new-onset CD or new-onset UC. In addition, significant dosedependent relationships between antibiotic use and the development of CD and UC were observed. This relationship existed irrespective of age groups and presented across 5 years before IBD diagnosis. The majority of antibiotic classes were associated with an increased risk of developing CD and UC. Our findings corroborate previous studies from the UK 20 and Canada. 16, 27 Card et al. used the General Practice Research Database and illustrated the association between antibiotic use and the development of CD. 20 They showed that antibiotic use increased the odds of CD by a factor of over 30% [AOR, 1.32; 95% CI, 1.05-1.65]. Shaw et al. performed a case-control study using the University of Manitoba IBD Epidemiology Database. 16 The authors found that the odds of IBD for those receiving antibiotic dispensation at 2-5 years before diagnosis was 1.29 [95% CI, 1.18-1.40] for CD and 1.26 [1.16-1.36] for UC. A dose-dependent relationship was shown. At 2 years before diagnosis, those receiving one or more and two or more antibiotic dispensations had a 1.27-and 1.48-fold increase in the odds of CD, respectively. The AOR of UC was 1.62 for three of more antibiotic dispensations. When stratifying by age groups, significant associations between antibiotic use within 2-5 years and adult-onset IBD were identified [AOR 1.32 for age 19-65 years and 1.25 for > 65 years]. 16 In a Manitoba nested case-control study, antibiotic use in the first year of life was associated with a 2.9-fold increased risk of new-onset IBD in childhood [age < 16 years] . 27 Despite the use of large administrative databases, studies that rely on drug dispensation codes have limitations, in particular confounding factors. Important potential confounding factors such as family history of IBD and cigarette smoking status use were unavailable. Furthermore, the database could not verify that a dispensed antibiotic was actually consumed.
A key strength of this study is that all incident IBD cases and controls were derived from a well-defined geographical region and mostly received the same healthcare provision. More than 95% of Olmsted County residents receive medical care from either Mayo Clinic Medical Center or Olmsted Medical Center. Because of the medical record linkage system [Rochester Epidemiology Project], which provides access to all local medical records, we were able to review data from all available patients from 5 years before the index date until the end of the study period. We were able to verify the data regarding antibiotic consumption and accounted for other confounding factors. However, this study also had some limitations. First, because of its retrospective nature, any data not recorded in the medical records would have been missed. Secondly, socioeconomic factors are associated with hygiene status and healthcare utilization. The socioeconomic status of Olmsted County residents is slightly higher than that of the Upper Midwest population and the entire US population. 23 In 2000, 91% of Olmsted County residents were highschool graduates compared to 86% of the Upper Midwest population and 80% of the entire US population. 23 Median 23 The relatively high socioeconomic status in the region may limit the generalizability of these data to populations with different socioeconomic characteristics. Thirdly, Olmsted County had less ethnic diversity than the US population [90% vs. 75% white] between 1970 and 2000. 23 However, this gap has narrowed: 85.7% of county residents were whites in 2010 compared with 74.8% of the US population. 28 This change is similar to other Western countries. For example, according to the Office for National Statistics of the United Kingdom, the percentage of whites in England and Wales decreased from 94.1% in 1991 to 86% in 2011. 29 Although there were changes in the ethnic diversity of the Olmsted County population, the generalization of these study results to populations with more heterogeneous ethnicity may not be applicable.
It is unclear why antibiotic use was associated with new-onset IBD. Our findings may support a role of microbiome alterations in the pathogenesis of IBD. Previous studies in healthy humans have suggested that antibiotic exposure perturbs the gut microbiota composition, 30, 31 and repeated antibiotic exposure results in persistent dysbiosis. 32, 33 Many studies consistently reported changes in the total numbers and diversity of the gut microbiota in IBD patients. 34 For instance, increases in the numbers of adherent-invasive Escherichia coli, Enterobacteriaceae and Fusobacteriaceae, and decreases in the numbers of Bacteroides, Bifidobacteriaceae and Clostridia have been reported in IBD patients. 1 In addition to quantitative changes in the bacteria comprising the gut microbiota, antibiotics may alter the functional composition of the gut microbiota, as well. 35 Recently, a longitudinal paediatric IBD cohort study has shown an increased gut microbial dysbiosis index in new-onset IBD patients when compared to healthy controls. 36 In CD patients, the dysbiosis index at diagnosis was predictive of subsequent disease severity defined by the Pediatric CD Activity Index. 36 Although we found a strong association and dose-response relationship between antibiotic use and the development of IBD, a possible triggering role of antibiotics in the onset of IBD should be interpreted with caution. First, not all classes of antibiotics have the same local effect on the gut microbiome. Metronidazole, which directly targets specific gut bacteria, showed the strongest association with the approximately three-fold increased risk for developing IBD in the Manitoba study. 16 In contrast to the Manitoba study, an increased risk for IBD in metronidazole was not observed in our study. The relatively small number of metronidazole users in our study may have contributed to the lack of statistical significance. For other classes of antibiotics, an approximately two-fold increased risk of IBD among each class of antibiotic [i.e. penicillins, cephalosporins, quinolones, sulfonamides, macrolides and tetracyclines.] was observed. Our results are line with previous studies. The Manitoba study showed significant associations with all types of antibiotics except clindamycin, with AORs of 1.12-2.86. 16 In a large retrospective cohort study from the UK, tetracycline use for acne therapy was associated with IBD development (hazard ratio [HR], 1.39; 95% CI, 1.02-1.90]. 37 Secondly, we examined antibiotic usage for 5 years prior to IBD diagnosis. We did not examine earlier periods or during the first year of life, which theoretically is the important period for development and adaptation of the gut microbiota. 1 Thirdly, antibiotic use may act as a surrogate marker for infection, leading to IBD development. A previous study found that the HR of developing IBD was 2.4 [95% CI, 1.7-3.3] in patients with acute gastroenteritis. 38 Hypothetically, either gastrointestinal tract infection or antibiotic use could be confounding factors. However, we found that only 3.9% of the IBD cases had a gastrointestinal tract infection. More than 70% of infections were ear, nose, throat and respiratory tract infections. These infection sites are concordant with a previous study of the association between antibiotic use in the first year of life and childhood-onset IBD. 27 In conclusion, antibiotic use was an independent risk factor for the development of both CD and UC in this population-based nested case-control study. The risk was increased among all age-onset of IBD. Further longitudinal prospective studies investigating the infection and antibiotic use in parallel with gut microbiome analysis in IBD are warranted to unravel the pathogenesis of IBD.
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